Although several studies confirmed the high prevalence of IDH mutations in AML, the prognostic impact remains controversial with conflicting evidence [3, 10–12], because IDH mutations frequently co-occur with NPM1 mutations, MLL partial tandem duplications, FLT3-ITD, or trisomy 8 [13–16]. This evidence concerns the gene IDH2 and acute myeloid leukemia.